Alterity Therapeutics (ATHE) Cash from Operations (2009 - 2020)

Alterity Therapeutics has reported Cash from Operations for 9 years, with the latest figure at -$6.2 million in Q2 2020.

• On a quarterly basis, Cash from Operations rose 36.76% year-over-year to -$6.2 million in Q2 2020; TTM through Jun 2020 was -$19.4 million, a 5.9% increase from a year earlier, with the FY2026 full-year figure at -$16.0 million, up 100.0% from the prior year.
• Cash from Operations was -$6.2 million for Q2 2020 at Alterity Therapeutics, down from $1.8 million in the prior quarter.
• The five-year high for Cash from Operations was $1.8 million in Q4 2019, with the low at -$9.8 million in Q2 2019.
• Average Cash from Operations over 5 years is -$3.7 million, with a median of -$4.6 million recorded in 2017.
• The sharpest annual moves came in 2018 and 2019: Cash from Operations tumbled 474.49% in 2018, then soared 134.1% in 2019.
• Over 5 years, Cash from Operations stood at -$465813.1 in 2016, then plunged by 93.6% to -$901823.1 in 2017, then slumped by 474.49% to -$5.2 million in 2018, then jumped by 134.1% to $1.8 million in 2019, then tumbled by 449.93% to -$6.2 million in 2020.
• The last three Cash from Operations figures came in at -$6.2 million (Q2 2020), $1.8 million (Q4 2019), and -$9.8 million (Q2 2019), per Business Quant data.